Shuguang Leng1,2,3, Brenda Diergaarde4,5,6, Maria A Picchi1, David O Wilson7, Frank D Gilliland8, Jian-Min Yuan9,10, Jill M Siegfried5, Steven A Belinsky1,2,11. 1. 1 Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico. 2. 2 Cancer Control Research Program and. 3. 3 School of Public Health, Qingdao University, Qingdao, Shandong, China. 4. 4 Department of Human Genetics and. 5. 5 Cancer Epidemiology and Prevention Program. 6. 6 Lung Cancer Program, and. 7. 7 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 8. 8 Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; and. 9. 9 Department of Epidemiology, Graduate School of Public Health, and. 10. 10 Division of Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. 11. 12 Cancer Genetics and Epigenetics Program, University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico.
Abstract
RATIONALE: Gene promoter hypermethylation detected in sputum assesses the extent of field cancerization and predicts lung cancer (LC) risk in ever-smokers. A rapid decline of FEV1 is a major driver for development of airway obstruction. OBJECTIVES: To assess the effects of methylation of 12 genes on FEV1 decline and of FEV1 decline on subsequent LC incidence using two independent, longitudinal cohorts (i.e., LSC [Lovelace Smokers Cohort] and PLuSS [Pittsburgh Lung Screening Study]). METHODS: Gene methylation was measured in sputum using two-stage nested methylation-specific PCR. The linear mixed effects model was used to assess the effects of studied variables on FEV1 decline. MEASUREMENTS AND MAIN RESULTS: A dose-dependent relationship between number of genes methylated and FEV1 decline was identified, with smokers with three or more methylated genes having 27.8% and 10.3% faster FEV1 decline than smokers with zero to two methylated genes in the LSC and PLuSS cohort, respectively (all P < 0.01). High methylation in sputum was associated with a shorter latency for LC incidence (log-rank P = 0.0048) and worse all-cause mortality (log-rank P < 0.0001). Smokers with subsequent LC incidence had a more rapid annual decline of FEV1 (by 5.2 ml, P = 0.038) than smoker control subjects. CONCLUSIONS: Gene methylation detected in sputum predicted FEV1 decline, LC incidence, and all-cause mortality in smokers. Rapid FEV1 decline may be a risk factor for LC incidence in smokers, which may explain a greater prevalence of airway obstruction seen in patients with LC.
RATIONALE: Gene promoter hypermethylation detected in sputum assesses the extent of field cancerization and predicts lung cancer (LC) risk in ever-smokers. A rapid decline of FEV1 is a major driver for development of airway obstruction. OBJECTIVES: To assess the effects of methylation of 12 genes on FEV1 decline and of FEV1 decline on subsequent LC incidence using two independent, longitudinal cohorts (i.e., LSC [Lovelace Smokers Cohort] and PLuSS [Pittsburgh Lung Screening Study]). METHODS: Gene methylation was measured in sputum using two-stage nested methylation-specific PCR. The linear mixed effects model was used to assess the effects of studied variables on FEV1 decline. MEASUREMENTS AND MAIN RESULTS: A dose-dependent relationship between number of genes methylated and FEV1 decline was identified, with smokers with three or more methylated genes having 27.8% and 10.3% faster FEV1 decline than smokers with zero to two methylated genes in the LSC and PLuSS cohort, respectively (all P < 0.01). High methylation in sputum was associated with a shorter latency for LC incidence (log-rank P = 0.0048) and worse all-cause mortality (log-rank P < 0.0001). Smokers with subsequent LC incidence had a more rapid annual decline of FEV1 (by 5.2 ml, P = 0.038) than smoker control subjects. CONCLUSIONS: Gene methylation detected in sputum predicted FEV1 decline, LC incidence, and all-cause mortality in smokers. Rapid FEV1 decline may be a risk factor for LC incidence in smokers, which may explain a greater prevalence of airway obstruction seen in patients with LC.
Entities:
Keywords:
cause of death; epigenetics; longitudinal studies; lung neoplasms; spirometry
Authors: Weiliang Qiu; Andrea Baccarelli; Vincent J Carey; Nadia Boutaoui; Helene Bacherman; Barbara Klanderman; Stephen Rennard; Alvar Agusti; Wayne Anderson; David A Lomas; Dawn L DeMeo Journal: Am J Respir Crit Care Med Date: 2011-12-08 Impact factor: 21.405
Authors: Brigitte N Gomperts; Avrum Spira; Pierre P Massion; Tonya C Walser; Ignacio I Wistuba; John D Minna; Steven M Dubinett Journal: Semin Respir Crit Care Med Date: 2011-04-15 Impact factor: 3.119
Authors: Shannon Bruse; Akshay Sood; Hans Petersen; Yushi Liu; Shuguang Leng; Juan C Celedón; Frank Gilliland; Bartolomé Celli; Steven A Belinsky; Yohannes Tesfaigzi Journal: Am J Respir Crit Care Med Date: 2011-09-08 Impact factor: 21.405
Authors: Akshay Sood; Hans Petersen; Christopher M Blanchette; Paula Meek; Maria A Picchi; Steven A Belinsky; Yohannes Tesfaigzi Journal: Am J Respir Crit Care Med Date: 2010-07-01 Impact factor: 21.405
Authors: Christine A Stidley; Maria A Picchi; Shuguang Leng; Randy Willink; Richard E Crowell; Kristina G Flores; Huining Kang; Tim Byers; Frank D Gilliland; Steven A Belinsky Journal: Cancer Res Date: 2010-01-12 Impact factor: 12.701
Authors: David O Wilson; Joel L Weissfeld; Carl R Fuhrman; Stephen N Fisher; Paula Balogh; Rodney J Landreneau; James D Luketich; Jill M Siegfried Journal: Am J Respir Crit Care Med Date: 2008-07-17 Impact factor: 21.405
Authors: Brian H Chen; Riccardo E Marioni; Elena Colicino; Marjolein J Peters; Cavin K Ward-Caviness; Pei-Chien Tsai; Nicholas S Roetker; Allan C Just; Ellen W Demerath; Weihua Guan; Jan Bressler; Myriam Fornage; Stephanie Studenski; Amy R Vandiver; Ann Zenobia Moore; Toshiko Tanaka; Douglas P Kiel; Liming Liang; Pantel Vokonas; Joel Schwartz; Kathryn L Lunetta; Joanne M Murabito; Stefania Bandinelli; Dena G Hernandez; David Melzer; Michael Nalls; Luke C Pilling; Timothy R Price; Andrew B Singleton; Christian Gieger; Rolf Holle; Anja Kretschmer; Florian Kronenberg; Sonja Kunze; Jakob Linseisen; Christine Meisinger; Wolfgang Rathmann; Melanie Waldenberger; Peter M Visscher; Sonia Shah; Naomi R Wray; Allan F McRae; Oscar H Franco; Albert Hofman; André G Uitterlinden; Devin Absher; Themistocles Assimes; Morgan E Levine; Ake T Lu; Philip S Tsao; Lifang Hou; JoAnn E Manson; Cara L Carty; Andrea Z LaCroix; Alexander P Reiner; Tim D Spector; Andrew P Feinberg; Daniel Levy; Andrea Baccarelli; Joyce van Meurs; Jordana T Bell; Annette Peters; Ian J Deary; James S Pankow; Luigi Ferrucci; Steve Horvath Journal: Aging (Albany NY) Date: 2016-09-28 Impact factor: 5.682
Authors: Wassim W Labaki; Lucas M Kimmig; Gökhan M Mutlu; MeiLan K Han; Surya P Bhatt Journal: Am J Respir Crit Care Med Date: 2019-06-15 Impact factor: 21.405
Authors: Jarrett D Morrow; Barry Make; Elizabeth Regan; MeiLan Han; Craig P Hersh; Ruth Tal-Singer; John Quackenbush; Augustine M K Choi; Edwin K Silverman; Dawn L DeMeo Journal: Am J Respir Crit Care Med Date: 2020-05-01 Impact factor: 21.405
Authors: Mathewos Tessema; Dereje D Tassew; Christin M Yingling; Kieu Do; Maria A Picchi; Guodong Wu; Hans Petersen; Scott Randell; Yong Lin; Steven A Belinsky; Yohannes Tesfaigzi Journal: Lung Cancer Date: 2020-05-25 Impact factor: 5.705
Authors: Shuguang Leng; Maria A Picchi; Paula M Meek; Menghui Jiang; Samuel H Bayliss; Ting Zhai; Ruslan I Bayliyev; Yohannes Tesfaigzi; Matthew J Campen; Huining Kang; Yiliang Zhu; Qing Lan; Akshay Sood; Steven A Belinsky Journal: Respir Res Date: 2022-09-08